From: Role of radiation therapy in primary tonsil large B cell lymphoma: a SEER-based analysis
Characteristic | Patient characteristics in raw data | Patient characteristics after propensity score matching | |||||
---|---|---|---|---|---|---|---|
Total | Chemotherapy | Combined modality therapy | P | Chemotherapy | Combined modality therapy | P | |
 | 1214 | 677 (55.8%) | 537 (44.2%) |  | 455 (50.0%) | 455 (50.0%) |  |
Age, y | Â | Â | Â | 0.115 | Â | Â | 0.342 |
 18–39 | 134 (11.0%) | 72 (10.6%) | 62 (11.5%) |  | 57 (12.5%) | 53 (11.6%) |  |
 40–64 | 556 (45.8%) | 295 (43.6%) | 261 (48.6%) |  | 202 (44.4%) | 224 (49.2%) |  |
 65+ | 524 (43.2%) | 310 (45.8%) | 214 (39.9%) |  | 196 (43.1%) | 178 (39.1%) |  |
Sex | Â | Â | Â | 0.986 | Â | Â | 0.544 |
 Male | 705(58.1%) | 393(58.1%) | 312 (58.1%) |  | 272 (59.8%) | 263 (57.8%) |  |
 Female | 509(41.9%) | 284(41.9%) | 225 (41.9%) |  | 183 (40.2%) | 192 (42.2%) |  |
Year of diagnosis |  |  |  | < 0.001 |  |  | 0.653 |
 1983–2001 | 327(26.9%) | 148(21.9%) | 179 (33.3%) |  | 124 (27.3%) | 118 (25.9%) |  |
 2002–2016 | 887(73.1%) | 529(78.1%) | 358 (66.7%) |  | 331 (72.7%) | 337 (74.1%) |  |
Race | Â | Â | Â | 0.123 | Â | Â | 0.066 |
 White | 943(78.2%) | 527(78.5%) | 416 (77.8%) |  | 369 (81.1%) | 356 (78.2%) |  |
 Black | 76(6.3%) | 49 (7.3%) | 27 (5.0%) |  | 31 (6.8%) | 22 (4.8%) |  |
 Other | 187(15.5%) | 95 (14.2%) | 92 (17.2%) |  | 55 (12.1%) | 77 (16.9%) |  |
Stage |  |  |  | < 0.001 |  |  | 0.912 |
 I | 431 (35.5%) | 213 (31.5%) | 218 (40.6%) |  | 179 (39.3%) | 182 (40.0%) |  |
 II | 611 (50.3%) | 336 (49.6%) | 275 (51.2%) |  | 229 (50.3%) | 232 (51.0%) |  |
 III | 77 (6.3%) | 58 (8.6%) | 19 (3.5%) |  | 17 (3.7%) | 16 (3.5%) |  |
 IV | 95 (7.8%) | 70 (10.3%) | 25 (4.7%) |  | 30 (6.6%) | 25 (5.5%) |  |
Marital status | Â | Â | Â | 0.031 | Â | Â | 0.493 |
 Married | 701 (60.5%) | 369 (57.7%) | 332 (64.0%) |  | 290 (63.7%) | 280 (61.5%) |  |
 Other | 457 (39.5%) | 270 (42.3%) | 187 (36.0%) |  | 165 (36.3%) | 175 (38.5%) |  |